What Biltricide Treats: Main Uses and Benefits

Biltricide is commonly used in clinical settings for conditions caused by parasitic flatworm infestation, and is widely used for schistosomiasis (blood flukes) and infections caused by specific liver flukes (Clonorchiasis and Opisthorchiasis). It is commonly used to help manage symptoms related to certain other worm infestations, including tapeworm. It is relevant in situations requiring the elimination of the parasitic cause, whether the infection is newly acquired or well-established. The primary therapeutic benefit is that it supports the elimination of the parasitic burden, which contributes to addressing the underlying parasitic cause.

Biltricide is relevant across therapeutic domains where the management of long-term disease progression, or morbidity, is a major focus. It is applied in conditions marked by a heightened risk of permanent organ damage, such as hepatic fibrosis or chronic urinary tract pathology. The main benefit provides support that helps ease the overall symptom load in conditions related to the parasitic cause. This treatment is applied when infections present with a significant parasitic burden, and is commonly used both for individual clinical treatment of confirmed cases and in large-scale Mass Drug Administration (MDA) programs in endemic regions.

---

Quick Note: Relevant Context for Systemic Consequences

• The medication is commonly used to address organ-specific functional stress and symptoms related to systemic imbalance caused by chronic flatworm presence.
• It is applied in clinical settings that involve acute or unstable symptom patterns, and contributes to easing the overall symptom load by targeting the root infectious cause.

Regulatory References

1. NIH MedlinePlus overview of Praziquantel

Biltricide (Praziquantel) eligibility is strictly defined by official regulatory guidelines, which identify specific populations that are permitted to use the medicine, as well as groups for whom use is contraindicated or restricted.

Official Regulatory Eligibility and Restrictions

Classification	Eligibility Rules
Allowed Use	Adults and pediatric patients aged 1 year and older are indicated for use. Patients with mild hepatic impairment (Child-Pugh Class A) are generally permitted.
Absolute Contraindications	The medicine must not be used in patients with known hypersensitivity to praziquantel, those with ocular cysticercosis, or those receiving concomitant therapy with rifampin.
Age and Condition Restrictions	Safety and efficacy have not been established for children younger than 1 year of age. Patients with moderate to severe hepatic impairment (Child-Pugh Class B or C) require specific caution and monitoring.

Pregnancy and Lactation Status

Biltricide is categorized as Pregnancy Category B and should be used during pregnancy only if clearly needed. For women who are breastfeeding, regulatory guidance requires that nursing be temporarily interrupted for 72 hours after treatment due to the excretion of praziquantel into breast milk. Additionally, caution is advised for older adults due to the higher likelihood of decreased renal function and in patients with a history of central nervous system involvement.

Biltricide (praziquantel) is extensively metabolized in the liver, primarily through the Cytochrome P450 (CYP) enzyme system, which makes it susceptible to multiple drug-drug and drug-food interactions.

Contraindicated Combinations

Concomitant use with strong CYP450 enzyme inducers, such as Rifampin, is contraindicated. These substances accelerate the drug's metabolism, which can lead to plasma levels of praziquantel falling below the therapeutic range, resulting in treatment failure. If treatment is necessary, Rifampin must be discontinued for four weeks before starting Biltricide, and may be restarted one day after the course is completed.

Other Significant Interactions

Interacting Product Category	Effect on Praziquantel Levels	Example Medicines/Products
Other CYP450 Inducers	Reduces plasma levels	Phenytoin, Phenobarbital, Carbamazepine, Dexamethasone, St John’s Wort
CYP450 Inhibitors	Increases plasma levels	Cimetidine, Ketoconazole, Itraconazole, Erythromycin
Food Product	Increases plasma levels	Grapefruit juice

Patients with moderate to severe liver impairment may also experience higher and more prolonged plasma concentrations of the drug due to reduced metabolism.

Calcium Ion Dysregulation and Spastic Paralysis

Praziquantel's action is initiated by the R-enantiomer selectively binding to targets like the Voltage-Operated Ca^2+ Channels (VOCCs) on the parasitic flatworm's muscle cells. This binding causes an immediate, massive, and uncontrolled influx of extracellular calcium ions (Ca^2+), leading directly to spastic, tetanic paralysis that results in the loss of muscle function required for tissue adherence.

---

Tegument Damage and Immune System Exposure

Simultaneously, the drug rapidly causes structural damage to the parasite's protective outer layer, the tegument, resulting in vacuolization and disintegration. This critical damage exposes the worm's internal antigens, which facilitates the exposure of parasitic antigens and enhances recognition by the host's immune cells.

---

Host Vascular Modulation and Strategic Clearance

A secondary, host-level effect involves the R-enantiomer acting as a partial agonist on host 5HT2B receptors, causing localized vasoconstriction. This physiological alteration induces the "hepatic shift," which strategically concentrates the now-paralyzed parasites in the liver's portal system, maximizing their exposure to immunological attack and subsequent clearance.

Biltricide is administered solely via the oral route as a 600 mg film-coated tablet. The tablet is scored with three notches, allowing for precise physical division into 150 mg segments to accurately meet weight-based dosing requirements. The medication is structured as a single-day, short-course regimen, administered in three divided doses over a 24-hour period.

The dosing is specific to the condition and based on the patient's body weight (mg/kg). For schistosomiasis, the required dose is 20 mg/kg per administration, while for clonorchiasis and opisthorchiasis, the required dose is 25 mg/kg per administration. Doses must be separated by an interval of 4 to 6 hours and must be consumed with water during meals.

The tablet or its segments must be swallowed whole and not chewed to prevent potential gagging or vomiting from the bitter taste. For children aged 1 year and older, or those who cannot swallow the tablet whole, it may be crushed and mixed with liquid or soft food, provided the mixture is consumed within one hour of preparation. Proper administration also requires avoiding grapefruit or grapefruit juice during the treatment period.

Research evidence / Overview of studies for Biltricide

Evidence for Use in Schistosomiasis (Blood Flukes)

Research has widely explored Biltricide for treating infections caused by the major types of Schistosoma blood flukes. The evidence base includes decades of Randomized Controlled Trials (RCTs) and large-scale systematic reviews that combine findings from multiple studies. These trials were primarily used to measure parasitological outcomes, such as the Cure Rate (the conversion from positive to negative egg status in stool or urine samples) and the Egg Reduction Rate (the measured decrease in the number of eggs).

Studies were focused heavily on School-Age Children (SAC), but research also examined adults in endemic regions. Studies reported patterns related to Cure Rate (the elimination of eggs) in the observed populations. The evidence base includes many studies, but there is limited information for long-term outcomes or the durability of the initial response beyond the short-term follow-up. Furthermore, findings were mixed when comparing the measured Cure Rates across different geographical regions and various Schistosoma species, indicating a degree of variability in the observed patterns.

---

Evidence for Use in Liver Fluke Infections (Clonorchiasis and Opisthorchiasis)

Clinical research has investigated Biltricide for its use against specific liver fluke infections, namely Clonorchiasis and Opisthorchiasis. These studies include Randomized Controlled Trials and systematic reviews that compare the medicine to other agents or different treatment schedules. Research examined the Egg Reduction Rate (ERR) and related parasitic outcomes.

Findings generally described consistent patterns in the Cure Rate measurements in the studied populations with light to moderate infection intensity. However, older studies synthesized in reviews were sometimes found to have limited information regarding standard methodological practices like reporting how participants were assigned to treatment groups.

---

Research on Morbidity Control and Long-Term Progression

Research has also explored studies related to morbidity control, examining outcomes related to advanced disease consequences associated with chronic flatworm presence. Studies monitored various markers of advanced disease, including changes in organ size, such as hepatomegaly (enlarged liver) or splenomegaly (enlarged spleen), assessed by ultrasound. Studies reported how some morbidity markers evolved in the observed populations over defined time intervals.

The synthesis of data for these long-term outcomes has shown significant statistical heterogeneity, meaning the results varied widely across different study settings. The overall certainty remains low for certain complex, long-term outcomes. Data for pregnant women remain insufficient, and long-term effects are not fully established for this population.

Key Studies & References

1. Clinical Efficacy and Tolerability of Praziquantel for Intestinal and Urinary Schistosomiasis—A Meta-analysis of Comparative and Non-comparative Clinical Trials
2. WHO guideline on control and elimination of human schistosomiasis

Common questions about Biltricide (FAQ)

---

Q: What are the most common side effects of Biltricide?

According to official product information, the most frequently reported reactions are considered 'Very Common,' affecting 10% or more of patients. These common side effects include headache, dizziness, fatigue, abdominal pain, nausea, vomiting, and urticaria (hives).

---

Q: Is it possible to take Biltricide if I am pregnant or breastfeeding?

Official regulatory documents categorize Biltricide for use during pregnancy only if the need is clearly established. For women who are breastfeeding, regulatory guidance states that nursing should be temporarily interrupted for 72 hours after receiving treatment, as the active ingredient is known to be excreted into breast milk.

---

Q: How long will it take for Biltricide to cure the infection?

The Biltricide treatment is administered as a single-day regimen, typically taken in three doses separated by a few hours. The time it takes to achieve a cure (the elimination of the parasite) is a clinical determination that is assessed by a healthcare provider following treatment.

---

Q: What is Biltricide used for?

Biltricide, containing the active ingredient praziquantel, is officially indicated as a trematodicide, a medicine used to kill parasitic flatworms. It is used to treat infections caused by all species of Schistosoma (often called blood flukes), as well as infections due to the liver flukes Clonorchiasis and Opisthorchiasis.

---

Q: Can Biltricide cause liver damage?

Regulatory safety information notes that some patients have experienced mild, temporary increases in liver enzymes (which are indicators of liver function). The medicine is metabolized by the liver, and caution is advised for patients who have pre-existing moderate or severe liver impairment.

How to Store and Dispose of Biltricide?

The storage and disposal requirements for Biltricide (praziquantel) are strictly defined by official regulatory labeling to ensure product stability and safety.

Storage Requirements

Biltricide tablets must be stored at a temperature below 86°F (30°C). It is mandatory to protect the medicine from light and avoid storing it above this maximum temperature. All medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Biltricide should be disposed of in accordance with local requirements for pharmaceutical waste. The product is not included on the list of medicines recommended for immediate flushing down the toilet. If disposing of the tablets in the household trash, official guidance instructs mixing them with an unappealing substance, such as coffee grounds, and sealing the mixture in a bag before discarding.